2332 related articles for article (PubMed ID: 24123533)
21. Intracellular redox-activated anticancer drug delivery by functionalized hollow mesoporous silica nanoreservoirs with tumor specificity.
Luo Z; Hu Y; Cai K; Ding X; Zhang Q; Li M; Ma X; Zhang B; Zeng Y; Li P; Li J; Liu J; Zhao Y
Biomaterials; 2014 Sep; 35(27):7951-62. PubMed ID: 24930850
[TBL] [Abstract][Full Text] [Related]
22. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles.
Pan L; Liu J; He Q; Wang L; Shi J
Biomaterials; 2013 Apr; 34(11):2719-30. PubMed ID: 23337327
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking.
Li JM; Wang YY; Zhao MX; Tan CP; Li YQ; Le XY; Ji LN; Mao ZW
Biomaterials; 2012 Mar; 33(9):2780-90. PubMed ID: 22243797
[TBL] [Abstract][Full Text] [Related]
24. The packaging of siRNA within the mesoporous structure of silica nanoparticles.
Li X; Xie QR; Zhang J; Xia W; Gu H
Biomaterials; 2011 Dec; 32(35):9546-56. PubMed ID: 21906804
[TBL] [Abstract][Full Text] [Related]
25. In Situ Synthesis of Ultrathin ZIF-8 Film-Coated MSNs for Codelivering Bcl 2 siRNA and Doxorubicin to Enhance Chemotherapeutic Efficacy in Drug-Resistant Cancer Cells.
Pan QS; Chen TT; Nie CP; Yi JT; Liu C; Hu YL; Chu X
ACS Appl Mater Interfaces; 2018 Oct; 10(39):33070-33077. PubMed ID: 30203954
[TBL] [Abstract][Full Text] [Related]
26. The intracellular controlled release from bioresponsive mesoporous silica with folate as both targeting and capping agent.
Guo R; Li LL; Zhao WH; Chen YX; Wang XZ; Fang CJ; Feng W; Zhang TL; Ma X; Lu M; Peng SQ; Yan CH
Nanoscale; 2012 Jun; 4(11):3577-83. PubMed ID: 22543578
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
28. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.
Li JM; Zhang W; Su H; Wang YY; Tan CP; Ji LN; Mao ZW
Int J Nanomedicine; 2015; 10():3147-62. PubMed ID: 25960653
[TBL] [Abstract][Full Text] [Related]
29. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
[TBL] [Abstract][Full Text] [Related]
30. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
31. Functional silica nanoparticles for redox-triggered drug/ssDNA co-delivery.
Ma X; Nguyen KT; Borah P; Ang CY; Zhao Y
Adv Healthc Mater; 2012 Nov; 1(6):690-7. PubMed ID: 23184818
[TBL] [Abstract][Full Text] [Related]
32. Hydroxylated Mesoporous Nanosilica Coated by Polyethylenimine Coupled with Gadolinium and Folic Acid: A Tumor-Targeted T(1) Magnetic Resonance Contrast Agent and Drug Delivery System.
Zhang G; Gao J; Qian J; Zhang L; Zheng K; Zhong K; Cai D; Zhang X; Wu Z
ACS Appl Mater Interfaces; 2015 Jul; 7(26):14192-200. PubMed ID: 26084052
[TBL] [Abstract][Full Text] [Related]
33. Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer.
Zhuang J; Chen S; Hu Y; Yang F; Huo Q; Xie N
Int J Nanomedicine; 2021; 16():1961-1976. PubMed ID: 33727809
[TBL] [Abstract][Full Text] [Related]
34. Light- and pH-responsive release of doxorubicin from a mesoporous silica-based nanocarrier.
Knežević NŽ; Trewyn BG; Lin VS
Chemistry; 2011 Mar; 17(12):3338-42. PubMed ID: 21337435
[No Abstract] [Full Text] [Related]
35. Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA.
Han L; Tang C; Yin C
Biomaterials; 2015 Aug; 60():42-52. PubMed ID: 25982552
[TBL] [Abstract][Full Text] [Related]
36. Hollow Mesoporous Silica@Metal-Organic Framework and Applications for pH-Responsive Drug Delivery.
Jia X; Yang Z; Wang Y; Chen Y; Yuan H; Chen H; Xu X; Gao X; Liang Z; Sun Y; Li JR; Zheng H; Cao R
ChemMedChem; 2018 Mar; 13(5):400-405. PubMed ID: 29337422
[TBL] [Abstract][Full Text] [Related]
37. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
[TBL] [Abstract][Full Text] [Related]
38. A targeted drug delivery system based on folic acid-functionalized upconversion luminescent nanoparticles.
Liang X; Fan J; Zhao Y; Cheng M; Wang X; Jin R; Sun T
J Biomater Appl; 2017 Apr; 31(9):1247-1256. PubMed ID: 28350205
[TBL] [Abstract][Full Text] [Related]
39. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
Li Z; Zhang L; Tang C; Yin C
Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
[TBL] [Abstract][Full Text] [Related]
40. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles.
Gao Y; Chen Y; Ji X; He X; Yin Q; Zhang Z; Shi J; Li Y
ACS Nano; 2011 Dec; 5(12):9788-98. PubMed ID: 22070571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
